BioMerieux's molecular diagnostics division remains an impressive near-term growth driver.
We plan to revisit our growth assumptions for BioMerieux after the company posted surprisingly strong first-quarter results. Even though a few temporary factors, including FilmArray’s benefit from a more virulent flu season, make this quarter’s results potentially difficult to extrapolate, underlying performance appeared strong, regardless. The changes may increase our fair value estimate, but we plan on leaving our narrow moat rating intact.Excluding a large 2.6% currency benefit in the quarte...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.